Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Aerosolized rAAT in Alpha 1-Antitrypsin Deficiency
NCT00161707Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2003
- Primary completion
- Oct 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Aerosolized, Recombinant Alpha 1-Antitrypsin in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Started Jan 2003; status: completed.
02
Drugs
Aerosolized, Recombinant Alpha 1-Antitrypsin
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00161707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161707.